Arbutus Biopharma: Roivant returns 8.97M shares

The transaction leaves Roivant Sciences Ltd. with 29,880,079 directly held Arbutus common shares.

Rhea-AI Filing Summary

Arbutus Biopharma Corp. reports that Roivant Sciences Ltd. returned 8,967,383 common shares to the issuer on October 1, 2026, at $5 per share. Roivant directly held 29,880,079 shares afterward. Roivant is a 10% owner and may be deemed a director by deputization; no Rule 10b5-1 plan is reported.

Insider Trade Summary

Disposition: 8,967,383 shares

Disposition 1 txn

Insider Roivant Sciences Ltd.

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Disposition	Common Shares	8,967,383	$5.00	$44.84M

Holdings After Transaction: Common Shares — 29,880,079 shares (Direct)

Key Figures

Common shares returned to issuer: 8,967,383 shares Reported transaction price: $5 per share Shares held after transaction: 29,880,079 shares

3 metrics

Common shares returned to issuer 8,967,383 shares Roivant Sciences Ltd.; October 1, 2026

Reported transaction price $5 per share October 1, 2026 disposition to issuer

Shares held after transaction 29,880,079 shares Direct holdings reported by Roivant Sciences Ltd.

Key Terms

Disposition to issuer, director by deputization, Section 16 of the Securities Exchange Act of 1934

3 terms

Disposition to issuer technical

"Disposition to issuer"

director by deputization regulatory

"director by deputization"

Section 16 of the Securities Exchange Act of 1934 regulatory

"Section 16 of the Securities Exchange Act of 1934"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ABUS shares did Roivant Sciences Ltd. return to Arbutus?

Roivant Sciences Ltd., reported as a 10% owner, returned 8,967,383 Arbutus common shares to the issuer on October 1, 2026, at $5 per share, and directly held 29,880,079 shares afterward.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 09:00 PM Accepted by SEC EDGAR 10/05/2026 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roivant Sciences Ltd.

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arbutus Biopharma Corp [ [ABUS] ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	10/01/2026		D		8,967,383	D	$5	29,880,079	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The Reporting Person may be deemed to be a "director by deputization" of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934 by virtue of the fact that Matthew Gline (a director of the Issuer who serves as Chief Executive Officer of the Reporting Person and is an employee of Roivant Sciences, Inc. ("RSI"), a subsidiary of the Reporting Person) and Joseph Bishop (who is an employee of RSI) each currently serve on the board of directors of the Issuer on behalf of the Reporting Person. Lindsay Androski, who also serves on the board of directors of the Issuer, is an employee of RSI and separately serves as President and Chief Executive Officer of the Issuer.

	By: /s/ Keyur Parekh, as Authorized Signatory	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)